✦ LIBER ✦

A phase 2 study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric cancer

✍ Scribed by Maurie Markman

Publisher: Springer-Verlag
Year: 1998
Tongue: English
Weight: 73 KB
Volume: 124
Category: Article
ISSN: 1432-1335
DOI: 10.1007/s004320050183

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of weekly high-dose 5-f

A phase II study of weekly high-dose 5-fluorouracil and leucovorin plus biweekly alternating doxorubicin and cisplatin for advanced gastric carcinoma

✍ M. Raida; R. Kath; M. Arnrich; G. Kähler; J. Scheele; K. Höffken 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 277 KB

A phase II trial of weekly high dose con

A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer

✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 2 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

A phase II study of paclitaxel combined

A phase II study of paclitaxel combined with infusional 5-fluorouracil and low-dose leucovorin for advanced gastric cancer

✍ Chong Kun Im; Hei-Cheul Jeung; Sun Young Rha; Nae Choon Yoo; Sung Hoon Noh; Jae 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 329 KB

Docetaxel, 5-fluorouracil, and leucovori

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

✍ Manuel Constenla; Ramon Garcia-Arroyo; Isabel Lorenzo; Nancy Carrete; Begoña Cam 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 78 KB

A phase III randomized study of 5-fluoro

A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer

✍ Noe Kyeong Kim; Young Suk Park; Dae Seog Heo; Cheolwon Suh; Si Young Kim; Keun C 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

Randomized phase III Study of 5-fluorour

Randomized phase III Study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer

✍ Dennie V. Jones; Roger J. Winn; Barry W. Brown; Lawrence B. Levy; Reginald P. Pu 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 501 KB

Background. Metastatic colorectal cancer is generally incurable. The most active regimen available, 5-fluorouracil(5-FU) and folinic acid (Leucovorin), produces response rates of approximately 25% to 30%. Methyl-lomustine is a nitrosourea with modest activity against colorectal cancer. A randomized